This data feed is not available at this time. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.

Long before the Iron Curtain slammed down, the Orient Express had won a reputation as Europe’s most exciting train for the countless fictional (and occasionally real) spy plots, love affairs, murders ...

LITS has pivoted from biotech to becoming a Litecoin treasury via a $100 million PIPE. LITS has so far bought around 929,548 Litecoin. It has become the first US exchange-listed company holding ...

LITS is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of LITS shares has decreased $0.02 since the market last closed. This is a 1.31 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) ...

Lite Strategy Rebrand Aligns with Company’s LTC Digital Asset Treasury Strategy Advised by GSR Ventures SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI” or the “Company”) today ...

MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI” or the “Company”) today announced that it will change its corporate name to Lite Strategy, Inc., reflecting the Company’s expansion into a pioneer in digital ...

Lite Strategy Rebrand Aligns with Company’s LTC Digital Asset Treasury Strategy Advised by GSR Ventures “Litecoin has proven itself for over a decade as one of the most secure, reliable, and scalable ...

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI” or the “Company”) today announced that it will change its corporate name to Lite Strategy, Inc., reflecting the Company’s expansion ...